Oct 27, 2020 by Jason HawthorneInvestors Betting on a Coronavirus Vaccine Better Know Who Gets First Dibs in Global PactThe World Health Organization is managing a global vaccine program without U.S. participation, and it could have a big impact for investors.
Oct 26, 2020 by Jason HawthorneBetter Buy: Amwell vs. TeladocBoth telehealth companies have seen growth accelerate during the pandemic, but your business philosophy may determine which stock is best for you.
Oct 26, 2020 by Jason HawthorneWhy Is Everyone Talking About Eastman Kodak Stock?The once-iconic American brand is making news for all the wrong reasons, and investors are hoping the story has a happy ending.
Oct 25, 2020 by Jason Hawthorne1 Truth and 1 Misconception About How the Election Will Change HealthcareThe past 10 years can tell us a lot about what will happen in healthcare after the November election, and what won't.
Oct 23, 2020 by Jason HawthorneWhy Europe Is Looking to This Company for a Coronavirus VaccineCureVac is using the same messenger RNA approach that Moderna uses. Why is Moderna getting all the headlines?
Oct 22, 2020 by Jason Hawthorne1 Green Flag for Teladoc's FutureInvestors were frightened by the $18.5 billion price tag for Livongo, but they might be missing the most important metric for valuing the company.
Oct 22, 2020 by Jason HawthorneIs OPKO Health Stock a Buy?Despite high-profile agreements to provide coronavirus testing, this small-cap company might not pass the test in the long term.
Oct 21, 2020 by Jason Hawthorne1 Red Flag for Teladoc's FutureCoronavirus relief packages eliminated restrictions on telemedicine. Growth for the company could hit a roadblock if these barriers are brought back.
Oct 19, 2020 by Jason HawthorneIs It Too Late to Buy Livongo Stock?The fast-growing chronic disease management company is getting swallowed up in one of the largest deals of the year, but it may not be too late to pick up shares.
Oct 18, 2020 by Jason HawthorneCan Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?Two small biotechs collaborated to find a coronavirus vaccine, but one of them may come out way ahead due to its expertise and other partnerships.
Oct 18, 2020 by Jason HawthorneDoes This Metric Tell Investors All They Need to Know About Gilead Sciences?The company has stagnated since its revolutionary HIV and hepatitis C drugs were released, and one metric shows why investors should look elsewhere for returns.
Oct 17, 2020 by Jason HawthorneBetter Coronavirus Stock: AstraZeneca or Johnson & JohnsonThese two pharma heavyweights are among the many players racing to get a COVID-19 vaccine approved.
Oct 17, 2020 by Jason HawthorneQuidel and OPKO Health Are Scoring With Coronavirus Testing in Sports. Is the Market Missing It?Successful partnerships with major sports leagues and updated guidance may mean coronavirus testing is here to stay.
Oct 17, 2020 by Jason HawthorneIs Amwell Stock a Buy?The stock has doubled since its hot IPO, but coronavirus-induced trends might not be enough to satisfy investors seeking outsized gains.
Oct 16, 2020 by Jason Hawthorne1 Reason to Sell Moderna NowBrisk executive stock sales raise serious questions about why retail investors should buy shares of this coronavirus vaccine developer.
Oct 16, 2020 by Jason Hawthorne1 Reason to Buy Moderna NowThe company is developing a software for our bodies that could redefine medicine in the years ahead.
Oct 14, 2020 by Jason HawthorneWhere Will Teladoc Be in 5 Years?The company should still be a compelling growth stock after the coronavirus, when things go back to normal (we hope). But investors might not care.
Oct 14, 2020 by Jason HawthorneBetter Buy: AbbVie vs. Johnson & JohnsonBoth are large pharmaceutical companies, but these stocks have some huge differences that can help investors pick the better long-term investment.
Oct 12, 2020 by Jason Hawthorne2 Top Healthcare Stocks to Watch in OctoberThese stocks could share big news this month, loosening the grip of the coronavirus on our lives.
Oct 11, 2020 by Jason HawthorneIs Gilead Sciences a Buy?Investors interested in Gilead Sciences need to look forward, not backward, to avoid the common trap of thinking history will repeat itself.
